▶ PEG-MGF · SUBTOPIC · SAFETY PROFILE
PEG-MGF Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of PEG-MGF.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of PEG-MGF. Severity, frequency, and attribution depend on the source publication.
- Injection-site reactions
- Local swelling/redness with IM administration
- Limited published Western safety data
- Theoretical hypoglycemia (IGF-1R activation)
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for PEG-MGF.
- Insulin / glucose-lowering agents (theoretical hypoglycemia risk via IGF-1R)
- Concurrent rhGH not recommended
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for PEG-MGF in the published record:
- Active malignancy
- Pregnancy/lactation
- Diabetic retinopathy
FDA REGULATORY STATUS
Not FDA-approved. Research-use only.
WADA REGULATORY STATUS
Prohibited at all times under WADA Section S2 (Growth Factors sub-category).
SAFETY Q+A FROM LITERATURE
▶ Is PEG-MGF FDA-approved?
No. Research-use only.
▶ Is PEG-MGF WADA-prohibited?
Yes. PEG-MGF is prohibited at all times under WADA Section S2 in the Growth Factors sub-category.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Goldspink G, Yang SY. Mechano growth factor and a method for improvement of muscle. J Musculoskelet Neuronal Interact 2002. link
- Hill M, Wernig A, Goldspink G. Muscle satellite (stem) cell activation during local tissue injury and repair. J Anat 2003. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25